Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of JKN2501 in Healthy Chinese Volunteers
NCT07207291Phase 1Recruiting
- Sponsor
- Joincare Pharmaceutical
- Start
- Aug 2025
- Primary completion
- Mar 2026
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of JKN2501 in bacterial infection, urinary tract infection (UTI), intra-abdominal infections (IAI) and 1 more (8 cohorts), sponsored by Joincare Pharmaceutical. Primary endpoint: Safety and Tolerability of Single and Multiple IV Infusions at Day 18. Started Aug 2025; status: recruiting.
02
Drugs
JKN2501
03
Conditions
bacterial infectionurinary tract infection (UTI)intra-abdominal infections (IAI)respiratory tract infection (RTI)
Beyond the preview
Go deeper on NCT07207291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07207291.